
## Wilhelmus J Kwanten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2143062/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	2.4	42
2	Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD. JHEP Reports, 2022, 4, 100412.	2.6	12
3	Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. Journal of Hepatology, 2021, 75, 292-301.	1.8	68
4	Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?― Journal of Hepatology, 2021, 75, 1513-1514.	1.8	0
5	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. Frontiers in Immunology, 2020, 11, 1711.	2.2	19
6	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 467-490.	2.3	26
7	Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. Nature Biomedical Engineering, 2020, 4, 801-813.	11.6	34
8	Portal Hypertension in NASH: Is It Different from Other Aetiologies?. Current Hepatology Reports, 2019, 18, 134-143.	0.4	1
9	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Frontiers in Immunology, 2019, 10, 82.	2.2	157
10	Sarcopenia in patients with nonâ€alcoholic fatty liver disease: is it a clinically significant entity?. Obesity Reviews, 2019, 20, 353-363.	3.1	42
11	The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Medical Hypotheses, 2019, 122, 188-197.	0.8	25
12	Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Laboratory Investigation, 2018, 98, 1263-1275.	1.7	33
13	Renin–Angiotensin System Inhibitors to Mitigate Cancer Treatment–Related Adverse Events. Clinical Cancer Research, 2018, 24, 3803-3812.	3.2	40
14	Autophagy determines efficiency of liverâ€directed gene therapy with adenoâ€associated viral vectors. Hepatology, 2017, 66, 252-265.	3.6	35
15	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. American Journal of Physiology - Renal Physiology, 2016, 311, G599-G609.	1.6	37
16	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. Journal of Hepatology, 2016, 65, 425-443.	1.8	366
17	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. World Journal of Gastroenterology, 2014, 20, 7325.	1.4	88
18	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Laboratory Investigation, 2012, 92, 1428-1439.	1.7	100

## IF CITATIONS

Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD). , 0, , .

ARTICLE

#